4% Dividend + 12x Earnings = Blockbuster in the Making
Merck has long been a pillar of stability in the pharmaceutical world, thanks in large part to the staggering success of its cancer drug Keytruda. But behind that success lies a quietly growing concern of what happens when the patents expire?
In a move that could reshape its future, Merck just announced a $10 billion acquisition of Verona Pharma.
» Read more about: 4% Dividend + 12x Earnings = Blockbuster in the Making »